Yuki Yoshikawa
Osaka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 86 publications
Timing-dependent skin toxicity phenotypes during enfortumab vedotin plus pembrolizumab therapy for advanced urothelial carcinoma.
Journal: International journal of clinical oncology
Published: June 04, 2026
Enfortumab vedotin plus pembrolizumab for recurrent metastatic urothelial carcinoma following adjuvant nivolumab.
Journal: Japanese journal of clinical oncology
Published: May 25, 2026
Author's reply to 'Bayesian interpretation of febrile neutropenia risk and primary G-CSF prophylaxis during darolutamide triplet therapy'.
Journal: Japanese journal of clinical oncology
Published: March 02, 2026
Learning curves of 13 surgeons for robot-assisted radical prostatectomy in a single institution: role of early case density.
Journal: Journal of robotic surgery
Published: February 08, 2026
A Two-Factor Bedside Prognostic Score Integrating Eastern Cooperative Oncology Group (ECOG) Performance Status and Aggressive Metastatic Burden in Metastatic Hormone-Sensitive Prostate Cancer.
Journal: The Prostate
Published: February 03, 2026
A ferroptosis-suppressive state drives resistance to bladder-preserving chemoradiotherapy in muscle-invasive bladder cancer.
Journal: Signal transduction and targeted therapy
Published: January 30, 2026
The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With First-Line ARPI Therapy.
Journal: The Prostate
Published: December 01, 2025
Real-world comparison of enzalutamide and apalutamide in metastatic hormone-sensitive prostate cancer: a multi-institutional propensity score-matched analysis.
Journal: Japanese journal of clinical oncology
Published: November 20, 2025
Last Updated: 09/26/2026